Hengrui Pharmaceutical (600276.SH): Application for marketing licensing of Heterripopa ethanolamine tablets was accepted

Zhitongcaijing · 10/15 07:49

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. The company received the “Notice of Acceptance” issued by the State Drug Administration. The company's application for marketing licensing of hichrapopa ethanolamine tablets was accepted by the State Drug Administration. The indications are: This product is combined with immunosuppressive treatment, suitable for patients aged 15 and above treated with severe aplastic anemia.